Covid-19 Flagship Project
In partnership with the OTAVA Ltd, our software has designed promising, novel antiviral medicines to combat Covid-19 which had promising In- Vitro Results.
Specifically, these drug candidates target the PLPro receptor, a key protein involved in the reproduction of the Coronavirus, opening a new door of opportunity to how we combat the pandemic. More information about the testing done to these molecules con be found in our BioRXV publication linked below
Academic Collaborations
Dr. Thomas Lectka With Johns Hopkins University
A project for Lipidemia with Dr. Leckta/Carnegie Institute (both projects bringing their molecules into the lab), with collaborative efforts for other diseases with John Hopkins researchers on the way.
Dr. Wayne Childers with
Temple University
Designing Inhibitors for the PI3Ka cancer targets, that influence breast and ovarian cancers. So far Dr. Childers candidates have had great success in IC50 tests.
Corporate Collaborations
Scripps Research Institute
Phronesis AI an Scripps Calibr are collaborating in designing numerous drugs for numerous compounds
*Use of the above logos represents an active or pending collaboration with the organization and does not signify any official endorsement of Phronesis Artificial Intelligence, Inc.*